In today’s ACT Brief, we examine who decides what trials measure, how designing for human thinking improves site execution, and how the FDA extended an immunotherapy to a new bladder cancer population.
News|Podcasts|April 9, 2026
ACT Brief: Diversity Built Into Trial Design, AI Impact Across Trial Lifecycle, and Companion Diagnostics Adoption
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we explore why clinical trial diversity requires protocol redesign from the outset, the highest-impact opportunities for AI across the complete trial lifecycle, and the regulatory and operational barriers slowing companion diagnostic adoption in oncology.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In part three of her
article series, Olga Elizarova, DDS, MPH, MBA, senior consultant behavioral science at S3 Connected Health, examined why diversity in clinical trials cannot be achieved through last-minute recruitment efforts. Meaningful representation requires designing protocols, sites, and enrollment strategies around the real barriers and needs of underrepresented communities from the outset, including accessible locations, flexible schedules, and investigators who reflect the communities being recruited. - In part four of his video
interview , Krishna Cheriath, vice president and head of clinical research digital data and AI at Thermo Fisher Scientific, mapped the highest-impact opportunities for AI across the trial lifecycle—from smarter protocol design and enrollment matching to data collection, cycle time compression, and the emerging potential of synthetic data in rare disease applications. - In a new contributed
article from Pharmaceutical Executive, companion diagnostics face significant adoption barriers including evidence generation timelines of five to ten years, transition from research-grade to clinical-grade assays, workflow integration challenges, and reimbursement delays. Pharma-diagnostic co-development with parallel validation and approval can accelerate access, while NGS-based platforms delivering results in 24 hours are enabling faster treatment decisions and stronger trial enrollment.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.
In today’s ACT Brief, we examine what it will take to scale EHR-to-EDC connections for real-time trials, how the FDA is reimagining rare disease drug development, and why oncology real-world evidence still faces persistent data barriers.
In today's ACT Brief, we examine how representation gaps in trials are shaped by structural design decisions, how new partnerships automate data transfer from site systems to sponsor platforms, and how Roche is licensing a novel obesity target from a biotech pioneer.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
In today's ACT Brief, we examine how AI surfaces design flaws before enrollment, why site training readiness depends on learning science, and the priorities defining next-generation weight-loss therapies.
In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
Trending on Applied Clinical Trials Online
1
What It Actually Means to Embed AI Across the Clinical Operating Model
2
Real-Time Clinical Trials Depend on a Scalable EHR-to-EDC Connection
3
2026 SCRS Global Site Solutions Summit: What Should Sponsors and CROs Change About How They Contract with a Network?
4
2026 SCRS Global Site Solutions Summit: What Causes Technology Adoption to Stall?
5